Revolution Medicine Shares Fall 6% and Zealand Pharma Announces Clinical Results
RVMD Revolution Medicines Inc
$189.76 +0.87%
View chart & analysis → 
- 1Revolution Medicine shares fell 6% following the release of FDA review documents.
- 2Zealand Pharma recorded a 9% weight reduction relative to body weight in obesity and diabetes patients during a 28-week Phase 2 clinical trial.
- 3The Phase 2 clinical trial for obesity and diabetes patients showed an additional 7 percentage point weight reduction compared to the placebo over 28 weeks.
So what's the key point?
Revolution Medicine shares dropped 6%. Zealand Pharma announced trial results showing that obesity patients lost 9% of their body weight.
Source BioPharma Dive · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.